IN2013DN02552A - - Google Patents

Download PDF

Info

Publication number
IN2013DN02552A
IN2013DN02552A IN2552DEN2013A IN2013DN02552A IN 2013DN02552 A IN2013DN02552 A IN 2013DN02552A IN 2552DEN2013 A IN2552DEN2013 A IN 2552DEN2013A IN 2013DN02552 A IN2013DN02552 A IN 2013DN02552A
Authority
IN
India
Prior art keywords
ht2c
benzazepine
tetrahydro
chloro
salts
Prior art date
Application number
Other languages
English (en)
Inventor
Anthony C Blackburn
Scott Stirn
Yun Shan
Anna Shifrina
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IN2013DN02552A publication Critical patent/IN2013DN02552A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2552DEN2013 2010-09-01 2011-08-31 IN2013DN02552A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40258910P 2010-09-01 2010-09-01
PCT/US2011/049953 WO2012030951A1 (en) 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists

Publications (1)

Publication Number Publication Date
IN2013DN02552A true IN2013DN02552A (cg-RX-API-DMAC7.html) 2015-08-07

Family

ID=44645827

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2552DEN2013 IN2013DN02552A (cg-RX-API-DMAC7.html) 2010-09-01 2011-08-31

Country Status (11)

Country Link
US (1) US20140148442A1 (cg-RX-API-DMAC7.html)
EP (1) EP2611781A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013536858A (cg-RX-API-DMAC7.html)
KR (1) KR20130138768A (cg-RX-API-DMAC7.html)
CN (1) CN103189358A (cg-RX-API-DMAC7.html)
AU (1) AU2011296027A1 (cg-RX-API-DMAC7.html)
CA (1) CA2808900A1 (cg-RX-API-DMAC7.html)
IN (1) IN2013DN02552A (cg-RX-API-DMAC7.html)
MX (1) MX2013002430A (cg-RX-API-DMAC7.html)
SG (2) SG10201506873WA (cg-RX-API-DMAC7.html)
WO (1) WO2012030951A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506870PA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
KR20180094131A (ko) 2010-09-01 2018-08-22 에자이 알앤드디 매니지먼트 가부시키가이샤 신장 손상을 갖는 개체에 대한 로카세린의 투여
WO2014058441A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
WO2014135545A1 (en) * 2013-03-05 2014-09-12 Sandoz Ag Solid dispersion comprising amorphous lorcaserin hydrochloride
WO2014187768A1 (en) * 2013-05-20 2014-11-27 Lek Pharmaceuticals D.D. Novel synthetic processes to 8-chloro-3-benzo[d]azepine via friedel-crafts alkylation of olefin
EP2868656A1 (en) * 2013-11-05 2015-05-06 LEK Pharmaceuticals d.d. Stabilized amorphous lorcaserin hydrochloride
CN104936947B (zh) * 2013-12-27 2017-03-08 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
WO2015161730A1 (zh) 2014-04-21 2015-10-29 杭州普晒医药科技有限公司 一种氯卡色林共晶及其制备方法、药物组合物和用途
CN103901151A (zh) * 2014-04-23 2014-07-02 湖北朗昕生化药业有限公司 一种hplc法检测氯卡色林盐酸盐含量的方法
TW201618787A (zh) 2014-10-30 2016-06-01 艾尼納製藥公司 組合物及方法
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
PT100602A (pt) * 1991-06-21 1993-09-30 Smithkline Beecham Plc Uso de derivados de tetra-hidrobenzazepinas, derivados de tetra-hidrobenzazepinas,sua preparacao e composicoes farmaceuticas que os contem
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
EP0804170B1 (en) 1993-07-09 2001-11-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
KR100353304B1 (ko) 1996-10-01 2002-09-30 에스알아이 인터내셔널 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US20030118078A1 (en) * 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
SI2332921T1 (sl) 2003-06-17 2016-06-30 Arena Pharmaceuticals, Inc. 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
JP4796047B2 (ja) * 2004-02-25 2011-10-19 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体作用薬としての６−置換２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
US8168624B2 (en) 2004-12-21 2012-05-01 Arena Pharmaceuticals, Inc. Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
EP2111859A1 (en) * 2004-12-23 2009-10-28 Arena Pharmaceuticals, Inc. 5HT2C receptor modulator compositions and methods of use
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007028131A1 (en) * 2005-09-01 2007-03-08 Eli Lilly And Company 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
JP5165568B2 (ja) * 2005-09-01 2013-03-21 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換−２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
JP5199997B2 (ja) * 2006-04-03 2013-05-15 アリーナ ファーマシューティカルズ， インコーポレイテッド ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
WO2008070111A2 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
WO2008081204A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
US20090143363A1 (en) * 2007-10-15 2009-06-04 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
CN102015591B (zh) 2008-03-04 2014-01-29 艾尼纳制药公司 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
CL2009000782A1 (es) 2008-03-31 2010-04-30 Metabolex Inc Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы

Also Published As

Publication number Publication date
JP2013536858A (ja) 2013-09-26
MX2013002430A (es) 2013-07-22
CA2808900A1 (en) 2012-03-08
KR20130138768A (ko) 2013-12-19
EP2611781A1 (en) 2013-07-10
AU2011296027A1 (en) 2013-04-04
WO2012030951A1 (en) 2012-03-08
SG10201506873WA (en) 2015-10-29
US20140148442A1 (en) 2014-05-29
CN103189358A (zh) 2013-07-03
SG188363A1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
IN2013DN02552A (cg-RX-API-DMAC7.html)
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
MY181898A (en) Heterocyclic compounds and uses thereof
PH12016500739B1 (en) Inhibitors of the fibrolast growth factor receptor
GB201017345D0 (en) Receptor antagonists
MX367795B (es) Inhibidores de cdk.
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
PH12013500065A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34559A (es) Inhibidores de bromodominios
IN2012DN06714A (cg-RX-API-DMAC7.html)
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
TW201144301A (en) Processes for preparing linezolid
MA34075B1 (fr) Composition pharmaceutique comprenant un dérivé pyrimidineone
MY165118A (en) Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2013002421A (es) Sales no hidroscopicas de agonistas de 5-ht2c.
IN2014DN11078A (cg-RX-API-DMAC7.html)
ZA201505170B (en) Tablets with improved acceptance and good storage stability
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
TR201102857A2 (tr) Telmisartan ve diüretik kombinasyonunun farmasötik formülasyonları.
IT1400702B1 (it) Apparecchiatura per l'imballaggio di carichi con pellicola termoretraibile, dotata di bruciatori regolabili.
UA51902U (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) в качестве способа фригопротекторного действия